Trial Outcomes & Findings for TMS for Improving Response Inhibition in Adolescents With OCD (NCT NCT05104697)

NCT ID: NCT05104697

Last Updated: 2025-01-28

Results Overview

Computerized task, where shorter response time (in milliseconds) indicates better performance

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

7 participants

Primary outcome timeframe

Change from pre (within 1 hour before) to post (within 1 hour after) intervention

Results posted on

2025-01-28

Participant Flow

Participants were recruited from a pediatric OCD specialty clinic between March 2022 and March 2023. Note that recruitment began in March 2022 before the first participant was formally enrolled on the study start date of April 1, 2022.

All enrolled participants were randomly assigned to a study arm.

Participant milestones

Participant milestones
Measure
TMS at Visit 1, Sham at Visit 2
At visit 1, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 2, participants will receive sham (fake) TMS in the same location. Transcranial Magnetic Stimulation: All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
Sham at Visit 1, TMS at Visit 2
At visit 2, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 1, participants will receive sham (fake) TMS in the same location. Transcranial Magnetic Stimulation: All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
Overall Study
STARTED
3
4
Overall Study
COMPLETED
3
3
Overall Study
NOT COMPLETED
0
1

Reasons for withdrawal

Reasons for withdrawal
Measure
TMS at Visit 1, Sham at Visit 2
At visit 1, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 2, participants will receive sham (fake) TMS in the same location. Transcranial Magnetic Stimulation: All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
Sham at Visit 1, TMS at Visit 2
At visit 2, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 1, participants will receive sham (fake) TMS in the same location. Transcranial Magnetic Stimulation: All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
Overall Study
Withdrawal by Subject
0
1

Baseline Characteristics

TMS for Improving Response Inhibition in Adolescents With OCD

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
TMS at Visit 1, Sham at Visit 2
n=3 Participants
At visit 1, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 2, participants will receive sham (fake) TMS in the same location. Transcranial Magnetic Stimulation: All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
Sham at Visit 1, TMS at Visit 2
n=4 Participants
At visit 2, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 1, participants will receive sham (fake) TMS in the same location. Transcranial Magnetic Stimulation: All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
Total
n=7 Participants
Total of all reporting groups
Age, Categorical
<=18 years
3 Participants
n=5 Participants
4 Participants
n=7 Participants
7 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Continuous
13.7 years
STANDARD_DEVIATION 1.2 • n=5 Participants
16.3 years
STANDARD_DEVIATION 1.0 • n=7 Participants
15.1 years
STANDARD_DEVIATION 1.7 • n=5 Participants
Sex/Gender, Customized
Male
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Sex/Gender, Customized
Female
2 Participants
n=5 Participants
3 Participants
n=7 Participants
5 Participants
n=5 Participants
Sex/Gender, Customized
Nonbinary
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
3 Participants
n=5 Participants
4 Participants
n=7 Participants
7 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
3 Participants
n=5 Participants
4 Participants
n=7 Participants
7 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
3 participants
n=5 Participants
4 participants
n=7 Participants
7 participants
n=5 Participants
Children's Yale Brown Obsessive Compulsive Scale (CYBOCS)
24.0 units on a scale
STANDARD_DEVIATION 1.7 • n=5 Participants
24.3 units on a scale
STANDARD_DEVIATION 5.3 • n=7 Participants
24.1 units on a scale
STANDARD_DEVIATION 3.8 • n=5 Participants

PRIMARY outcome

Timeframe: Change from pre (within 1 hour before) to post (within 1 hour after) intervention

Population: Does not include data from one participant who withdrew prior to completing the measure

Computerized task, where shorter response time (in milliseconds) indicates better performance

Outcome measures

Outcome measures
Measure
Active TMS
n=6 Participants
Visits at which participants received active TMS using continuous theta burst over the preSMA. Note that all participants received both Sham and TMS; N for each "group" reflects the entire participant sample.
Sham (Fake) TMS
n=6 Participants
Visits at which participants received sham (fake) TMS. Note that all participants received both Sham and TMS; N for each "group" reflects the entire participant sample.
Change in Response Time on Stop Trials of the Stop Signal Task
-26.2 milliseconds
Standard Deviation 102.1
-31.7 milliseconds
Standard Deviation 123.1

PRIMARY outcome

Timeframe: Change from pre (within 1 hour before) to post (within 1 hour after) intervention

Population: Does not include data from two participants (one withdrew before completing the measure, one could not be analyzed due to error with EEG data capture)

Electroencephalogram (EEG) measured amplitude on successful stop trials of the stop signal task (SST). Calculated by averaging the epochs of successful stop trials time-locked to the stop signal from the midline electrode (Cz).

Outcome measures

Outcome measures
Measure
Active TMS
n=5 Participants
Visits at which participants received active TMS using continuous theta burst over the preSMA. Note that all participants received both Sham and TMS; N for each "group" reflects the entire participant sample.
Sham (Fake) TMS
n=5 Participants
Visits at which participants received sham (fake) TMS. Note that all participants received both Sham and TMS; N for each "group" reflects the entire participant sample.
Change in Frontocentral P3 Amplitude on Electroencephalogram (EEG)
0.5 microvolts (µV)
Standard Deviation 2.9
1.5 microvolts (µV)
Standard Deviation 2.2

SECONDARY outcome

Timeframe: post (within 1 hour after) intervention

Population: Does not include one participant who withdrew before completing measure

Self-rated compulsions on a single-item 0-5 scale, where higher scores indicate more compulsions

Outcome measures

Outcome measures
Measure
Active TMS
n=6 Participants
Visits at which participants received active TMS using continuous theta burst over the preSMA. Note that all participants received both Sham and TMS; N for each "group" reflects the entire participant sample.
Sham (Fake) TMS
n=6 Participants
Visits at which participants received sham (fake) TMS. Note that all participants received both Sham and TMS; N for each "group" reflects the entire participant sample.
Self-report Symptom Question
2.7 units on a scale
Standard Deviation 1.4
2.5 units on a scale
Standard Deviation 2.1

Adverse Events

Active TMS

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Sham (Fake) TMS

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Active TMS
n=6 participants at risk
Visits at which participants received active TMS using continuous theta burst over the preSMA. Note that all participants received both Sham and TMS; N for each "group" reflects the entire participant sample.
Sham (Fake) TMS
n=6 participants at risk
Visits at which participants received sham (fake) TMS. Note that all participants received both Sham and TMS; N for each "group" reflects the entire participant sample.
Nervous system disorders
Headache
0.00%
0/6 • Data were collected at one of two study visits that occurred over the course of two weeks
16.7%
1/6 • Number of events 1 • Data were collected at one of two study visits that occurred over the course of two weeks
Nervous system disorders
Scalp discomfort
16.7%
1/6 • Number of events 1 • Data were collected at one of two study visits that occurred over the course of two weeks
0.00%
0/6 • Data were collected at one of two study visits that occurred over the course of two weeks

Additional Information

Dr. Kristen Benito

Emma Pendleton Bradley Hospital

Phone: 401-432-1054

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place